TrialPloS one2019

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.

Paul Germonpré et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.